Leaderboards/Potassium and Related Disorders

Potassium and Related Disorders

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Foong Way David Tai
Royal Hallamshire Hospital
2
Silvia J. Leon
BioTillion (United States)
3
Abinet Abebe
Mizan Tepi University
4
Ahmad Qarajeh
University of Jordan
5
John W. Ostrominski
Brigham and Women's Hospital
6
Martin Gritter
Erasmus MC
7
Ingrid Hougen
University of Manitoba
8
Amélie Bernier-Jean
Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal
9
Aleksey M. Chaulin
Samara State Medical University
10
Chih‐Yuan Niu
Taipei Veterans General Hospital

Rising Stars Papers

1
Contemporary American and European Guidelines for Heart Failure Management
JACC Heart Failure|2024
68 cit.
2
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Journal of the American College of Cardiology|2024
41 cit.
3
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Journal of the American College of Cardiology|2025
20 cit.
4
Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States
Annals of Internal Medicine|2025
18 cit.
5
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
European Heart Journal|2024
11 cit.
6
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure
Journal of Cardiac Failure|2024
10 cit.
7
Finerenone Across the Spectrum of Kidney Risk in Heart Failure
JACC Heart Failure|2025
10 cit.
8
State-Level Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in the United States, 2011 to 2023
JACC Advances|2025
10 cit.
9
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction
JACC Heart Failure|2025
10 cit.
10
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease
Journal of the American College of Cardiology|2025
10 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
WC Winkelmayer
Unknown
2
Michael R. Schlabach
Q Therapeutics (United States)
3
Yohannes Wobie Wondimhunegn
Mizan Tepi University
4
Brit Long
University of Virginia
5
Katherine Menson
University of Vermont
6
Kristian Aasbjerg
Aarhus University Hospital
7
Glynnis Knobloch
Grant Medical Center
8
Jacob C. Jentzer
Mayo Clinic
9
Mark Glover
University of Alberta
10
Guillaume Grzych
Centre Hospitalier Universitaire de Lille

Emerging Leaders Papers

1
Potassium Disorders: Hypokalemia and Hyperkalemia.
PubMed|2023
122 cit.
2
Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock
Journal of the American Heart Association|2022
70 cit.
3
Advances in the Staging and Phenotyping of Cardiogenic Shock
JACC Advances|2022
54 cit.
4
Cardiovascular Events Among Survivors of Sepsis Hospitalization: A Retrospective Cohort Analysis
Journal of the American Heart Association|2023
48 cit.
5
Timing of Initiation of Extracorporeal Membrane Oxygenation Support and Outcomes Among Patients With Cardiogenic Shock
Journal of the American Heart Association|2024
47 cit.
6
Machine Learning Approaches for Phenotyping in Cardiogenic Shock and Critical Illness
JACC Advances|2022
46 cit.
7
Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock
Circulation Heart Failure|2023
46 cit.
8
Validation of cardiogenic shock phenotypes in a mixed cardiac intensive care unit population
Catheterization and Cardiovascular Interventions|2022
43 cit.
9
Cardiogenic shock severity and mortality in patients receiving venoarterial extracorporeal membrane oxygenator support
European Heart Journal Acute Cardiovascular Care|2022
43 cit.
10
Nitrous Oxide Abuse: Clinical Outcomes, Pharmacology, Pharmacokinetics, Toxicity and Impact on Metabolism
Toxics|2023
38 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Rinaldo Bellomo
The University of Melbourne
2
Bertram Pitt
Bayer (Germany)
3
Donald A. Redelmeier
Sunnybrook Health Science Centre
4
Austin G. Stack
University of Limerick
5
Barry F. Uretsky
Central Arkansas Veterans Healthcare System
6
Friedrich K. Port
Arbor Research Collaborative for Health
7
David A. Bushinsky
University of Rochester
8
Charles A. Herzog
Hennepin Healthcare Research Institute
9
Anne M. Murray
Hennepin County
10
Shuling Li
Laboratoire de Chémo-biologie synthétique et thérapeutique

Current Senior Leaders Papers

1
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
New England Journal of Medicine|1999
9.1k cit.
2
Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant
New England Journal of Medicine|1999
5.3k cit.
3
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Survey of Anesthesiology|2000
2.9k cit.
4
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
The Lancet|2000
2k cit.
5
Cardiorenal Syndrome
Journal of the American College of Cardiology|2008
1.8k cit.
6
Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study
New England Journal of Medicine|2004
1.8k cit.
7
Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012
JAMA|2014
1.7k cit.
8
When More Pain Is Preferred to Less: Adding a Better End
Psychological Science|1993
1.5k cit.
9
Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure
Circulation|1999
1.2k cit.
10
Association of Elevated Serum PO4, Ca × PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients
Journal of the American Society of Nephrology|2001
1.2k cit.

Reagents for Potassium and Related Disorders

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

Total SAPK/JNK Matched Antibody Pair

#74090$1,726
View Evidence →
Cell Signaling TechnologyEvidence 64

Phospho-Syk (Tyr525/526) (C87C1) Rabbit Monoclonal Antibody (Alexa Fluor® 647 Conjugate)

#12081$191,493
View Evidence →
Cell Signaling TechnologyEvidence 66

c-Fos (9F6) Rabbit Monoclonal Antibody (Alexa Fluor® 647 Conjugate)

#14188$465
View Evidence →